Piramal Pharma Limited’s Sellersville Facility Undergoes US FDA Inspection
Piramal Pharma Limited recently underwent a Good Manufacturing Practices (GMP) inspection of its Sellersville (USA) facility by the US Food and Drug Administration (US FDA). The inspection took place from May 4, 2026, to May 8, 2026.Following the conclusion of the inspection, the US FDA issued a Form-483, identifying three observations. During the closing meeting, these observations were recommended to be classified under Voluntary Action Indicated (VAI) by the inspectors. The company confirmed that none of the observations related to data integrity.
Piramal Pharma Limited stated that it is currently preparing a detailed response addressing the observations. This comprehensive response will be submitted to the US FDA within the stipulated timelines. The company emphasized its sustained commitment to maintaining the highest standards of compliance and affirmed that it will work closely with the agency to fully address all noted observations.
PPLPHARMA Stock Price Movement
On Friday, Piramal Pharma Limited shares slipped by 2.26% to close at ₹179.85, shedding ₹4.15 from previous trading levels. The equity settled after recording a significant total trading volume of 6.18 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.